Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

This study compares two treatment combinations for women with triple-negative breast cancer (TNBC) that has spread to other parts of the body and whose tumors do not respond well to immunotherapy (PD-L1 negative). Researchers are testing whether adding an immunotherapy drug (durvalumab) to a new antibody-drug combination (datopotamab deruxtecan) improves outcomes compared to the antibody-drug alone. **You may be eligible if...** - You are a female aged 18 or older - Your breast cancer is triple-negative (no estrogen receptor, no progesterone receptor, no HER2 amplification) - Your tumor tests negative for PD-L1 (a marker used to predict immunotherapy response) - You have at least one measurable tumor that has not been previously irradiated - You have tumor tissue available for central testing **You may NOT be eligible if...** - Your tumor is not triple-negative - You have sclerotic (hardening) bone lesions only with no measurable soft tissue disease - You cannot be assessed by CT or MRI Talk to your doctor to see if this trial is right for you.